Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/04/09
Hope JM et al. – Even after countered with and responding to maximal surgical and chemotherapy efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall recurrence is maintenance chemotherapy, an extension of treatment following a complete response to conventional measures. Many agents have been studied and many more are currently under investigation in maintenance regimens. While phase III data suggest that taxane maintenance prolongs progression–free survival, no overall survival benefit has been established. This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials.
Related Articles
Accuracy of reporting current medications by cancer patients presenting to an emergency center
Supportive Care in Cancer, 11/11/09
Relevance Score: 88%
Medical Management of Ulcerative Colitis
Digestive Diseases, 11/09/09
Relevance Score: 87%
Ovarian epithelial tumors of low malignant potential: a case series of 5 adolescent patients
Journal of Pediatric Surgery, 10/26/09
Relevance Score: 80%
Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue
Expert Review of Anticancer Therapy, 10/22/09
Relevance Score: 80%
Management of hypertension in the elderly patient
Clinical Interventions in Aging, 10/01/09
Relevance Score: 80%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis
Oncogene, 11/25/09
Paracentesis in Ovarian Cancer: A Study of the Physiology during Free Drainage of Ascites
Journal of Palliative Medicine, 11/25/09
How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component
Clinical and Translational Oncology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


